PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

2026 ISH Global Hypertension Practice Guidelines: Treat Elevated BP, Standardise Measurement, Task-Share

★ Editor's Pick2026 ISH Global Hypertension Practice GuidelinesInternational Society of Hypertensionhypertensionsingle-pill combinationsACEI/ARBCCBthiazide-like diureticsspironolactonealdosterone synthase inhibitorsendothelin receptor antagonistsnonsteroidal MRASGLT2 inhibitorshome blood pressure monitoring Cardiology

Background Information

New 2026 guidelines transform global hypertension management.

The 2026 guidelines provide updated recommendations for hypertension management worldwide, impacting global clinical practice. The guidelines emphasize individualized treatment strategies and the importance of lifestyle interventions alongside medication management. These updated guidelines inform drug therapy choices and lifestyle modifications, essential for pharmacists managing hypertensive patients. The 2026 guidelines emphasize personalized treatment and lifestyle changes in hypertension management.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Stergiou GS, Kario K, Aristizabal D, Beheiry H, Cho MC, Colombari DSA, Itoh H, Jafar TH, Jones E, Li Y, Romero CA, Steckelings UM, Williams B, Borghi C, Charchar F, Doku A, Dorobantu M, Flynn J, Khan N, Kollias A, Kreutz R, Mahmud A, Mancia G, Parati G, Poulter N, Reckelhoff J, Renna N, Shehab A, Schlaich M, Schutte A, Teo BW, Tomaszewski M, Touyz R, Wang J, Weber T, Whelton P, Zhang Y

Citation: Stergiou GS, Kario K, Aristizabal D, et al. 2026 International Society of Hypertension Global Hypertension Practice Guidelines. Journal of hypertension. 2026. doi:10.1097/HJH.0000000000004451

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.